Monitor for upcoming dosimetry and safety data in mid-to-late 2026, which could de-risk the program and trigger investor interest. Given CLRB's $12M market cap, even modest positive signals may lead to volatility, but any toxicity findings or delays could severely impact valuation.
Price Chart
Executive Summary
Cellectar Biosciences announced the first patient enrollment in its Phase 1b trial of CLR 125 for triple negative breast cancer (TNBC), marking a clinical advancement for its radioconjugate platform. The trial will evaluate three dosing regimens in relapsed/refractory TNBC patients, with safety, dosimetry, and efficacy updates expected throughout 2026. While preclinical data showed tumor uptake and no observed toxicity, this early-stage trial carries high risk given the company's small market cap and developmental stage.
Key Facts
- First patient enrolled in Phase 1b trial of CLR 125 for triple negative breast cancer (TNBC)
- CLR 125 is an Auger-emitting radioconjugate using iodine-125, with identical molecular structure to CLR 131 but different radiobiologic behavior
- Preclinical studies showed selective tumor uptake and significant activity in TNBC models with no observed end-organ or hematologic toxicity
- Phase 1b trial is dose-escalation, enrolling ~15 patients per arm across three regimens: 32.75 mCi (4 cycles), 62.5 mCi (3 cycles), 95 mCi (2 cycles)
- Endpoints include safety, tumor response (RECIST), and progression-free survival; imaging used to assess tumor uptake
- Additional trial sites to be activated in Q2 2026; updates expected throughout 2026
Financial Impact
No immediate financial impact; potential long-term value if clinical efficacy is demonstrated in a high-unmet-need population
Risk Factors
- Early-phase trial (Phase 1b) with high failure risk
- Limited financial resources; potential need for future dilutive financing
- No guarantee of clinical efficacy despite favorable preclinical data
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3273404 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $1.19 | awaiting T+60 | — | $1.22 (+2.52%) |
Aug 13, 2026 10w ago | 8-K | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Aug 13, 2026 10w ago | Press Release | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Jun 1, 2026 21w ago | Press Release | $2.97 $2.54 | ▼ −14.48% | ▼ −15.71% | $1.22 (−58.92%) |
May 29, 2026 21w ago | S-1/A | $3.14 $2.52 | ▲ +19.75% | ▲ +20.93% | $1.22 (+61.15%) |
May 28, 2026 21w ago | DEFA14A | $3.14 $2.52 | ▼ −19.75% | ▼ −20.93% | $1.22 (−61.15%) |
May 19, 2026 22w ago | S-1 | $3.17 $2.60 | ▲ +17.98% | ▲ +22.98% | $1.22 (+61.51%) |
May 14, 2026 23w ago | 8-K | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 14, 2026 23w ago | Press Release | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 11, 2026 24w ago | Press Release | $3.06 $2.52 | ▼ −17.65% | ▼ −22.04% | $1.22 (−60.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers